

**Australian Government** 

## **Department of Health**

## Therapeutic Goods Administration

Public Summary

Summary for ARTG Entry:	233639	METAGENICS GLUTATHIONE CAPSULES 250mg
ARTG entry for	Medicine Listed	
Sponsor	Metagenics (Aust	t) Pty Ltd
Postal Address	PO Box 675, VIR Australia	GINIA BC, QLD, 4014
ARTG Start Date	11/02/2015	
Product Category	Medicine	
Status	Active	
Approval Area	Listed Medicines	

Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.

The sponsor shall not supply the listed medicine after the expiry date of the goods.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

## Products

Product Type	Single Medicine Product	Effective Date	25/02/2020
Permitted Indication	ns		
Antioxidant/Reduce f	ree radicals formed in the body		
Helps reduce/decrea	se free radical damage to body cells		
ndication Requiren	nents		
No Indication Require	ements included on Record		
Standard Indication	IS		
No Standard Indication	ons included on Record		
Specific Indications	5		
No Specific Indication	ns included on Record		
Warnings			
If symptoms persist o Adults only.	consult your healthcare practitioner (or word	ds to that effect).	
Not recommended fo	or use by pregnant and lactating women (or	words to that effect).	
Additional Product	information		
Pack Size/Poison in	oformation		
Pack Size		Poison Schedule	
Components			
1. Formulation 1			
Dosage Form	Capsule, hard		
Route of Adminis	tration Oral		
Page 1 of 2			Produced at 31.08 2021 at 06:08:28 AEST

This is not an ARTG Certificate document.

The onus is on the reader to verify the current accuracy of the information on the document subsequent to the date shown. Visit www.tga.gov.au for contact information



**Australian Government** 

**Department of Health** Therapeutic Goods Administration

Visual Identification

Active Ingredients

glutathione

**Other Ingredients (Excipients)** 

calcium hydrogen phosphate dihydrate disodium edetate gellan gum hypromellose magnesium stearate potable water potassium acetate

silicon dioxide

250 mg

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at http://www.tga.gov.au/about/website-copyright.htm.

The onus is on the reader to verify the current accuracy of the information on the document subsequent to the date shown. Visit www.tga.gov.au for contact information

This is not an ARTG Certificate document.